Bigatab 90 mg (Brigatinib) Tablets – Advanced Treatment for ALK+ NSCLC
Overview
Bigatab 90 mg (Brigatinib) is a specialized tyrosine kinase inhibitor developed for patients with Anaplastic Lymphoma Kinase-positive (ALK+) non-small cell lung cancer (NSCLC). Manufactured by the renowned Eskayef Pharmaceuticals Ltd and distributed globally by Saif Pharma, Bigatab represents a breakthrough in targeted cancer therapy, offering hope to patients requiring effective ALK inhibition treatment.
Mechanism of Action
Brigatinib, the active ingredient in Bigatab, functions through potent and selective inhibition of multiple kinases at clinically achievable concentrations. Its primary targets include:
- Anaplastic Lymphoma Kinase (ALK)
- ROS1 tyrosine kinase
- Insulin-like Growth Factor-1 Receptor (IGF-1R)
- FLT-3 (FMS-like tyrosine kinase 3)
- EGFR (Epidermal Growth Factor Receptor) deletion and point mutations
This comprehensive inhibitory action disrupts the autophosphorylation of ALK and blocks ALK-mediated phosphorylation of downstream signaling proteins, including STAT3, AKT, ERK1/2, and S6. By interfering with these critical cellular pathways, Bigatab effectively halts the proliferation of cancer cells dependent on these oncogenic drivers.
Clinical Applications
Bigatab is primarily indicated for patients with ALK-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to other ALK inhibitor treatments. Clinical studies have demonstrated impressive response rates, including in patients with:
- ALK-positive NSCLC with brain metastases
- Crizotinib-resistant ALK+ NSCLC
- Previously untreated ALK+ locally advanced or metastatic NSCLC
Dosage & Administration
Bigatab 90 mg tablets are typically administered as part of a carefully monitored treatment regimen. The standard dosing protocol should be determined by healthcare professionals based on patient-specific factors. Always follow your oncologist’s prescription and guidelines for optimal results.
Product Quality Assurance
Manufactured by Eskayef Pharmaceuticals Ltd, one of Bangladesh’s leading pharmaceutical companies with over three decades of experience, Bigatab adheres to stringent quality control measures and international manufacturing standards. Eskayef’s state-of-the-art production facilities ensure consistent potency, purity, and efficacy in every tablet.
Global Availability
Through Saif Pharma’s extensive distribution network spanning 60+ countries, Bigatab 90 mg is accessible to patients worldwide, including major markets such as:
- United States
- Canada
- Saudi Arabia
- United Arab Emirates
- China
- India
- Pakistan
Advantages of Bigatab
- Targeted Therapy: Specifically designed to address ALK+ cancer cells while minimizing damage to healthy tissue
- Multi-Kinase Inhibition: Effective against multiple oncogenic drivers for comprehensive treatment
- Breakthrough Option: Provides new hope for patients who have developed resistance to first-generation ALK inhibitors
- Quality Assured: Manufactured under strict quality control by Eskayef Pharmaceuticals
- Global Access: Available worldwide through Saif Pharma’s established distribution network
- Cost-Effective: Offered at competitive pricing to improve accessibility for patients globally
About the Manufacturer
Eskayef Pharmaceuticals Ltd began its journey in 1990 when Bangladesh operations of SK&F, USA were acquired by the respected Transcom Group. For over 31 years, Eskayef has built a reputation for premium quality pharmaceuticals, serving both domestic and international markets with world-class medicines.
About the Supplier
Founded in 2014, Saif Pharma has established itself as a leading supplier, trader, and distributor of oncology medicines. With a mission centered on providing high-quality, affordable cancer treatments, Saif Pharma has earned a prestigious market position by prioritizing dependability and patient access. Their extensive global network ensures that vital medications like Bigatab reach patients worldwide, reducing suffering and improving treatment outcomes.
Commitment to Patient Care
Both Eskayef Pharmaceuticals and Saif Pharma share a commitment to advancing cancer care through high-quality, accessible medications. Bigatab 90 mg represents this shared mission, offering a scientifically advanced treatment option that can significantly improve outcomes for ALK+ NSCLC patients.
For more information about Bigatab 90 mg (Brigatinib) or to inquire about availability in your region, please visit www.saifpharma.com or contact your healthcare provider.
